(Q38524502)

3 September 2017

1 reference

title

Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments (English)

1 reference

3 September 2017

1 reference

J A Ledermann

1

1 reference

3 September 2017

S Canevari

series ordinal

2

1 reference

3 September 2017

T Thigpen

series ordinal

3

1 reference

3 September 2017

publication date

10 June 2015

1 reference

3 September 2017

1 reference

3 September 2017

volume

26

1 reference

3 September 2017

issue

10

1 reference

3 September 2017

page(s)

2034-2043

1 reference

Systemic cancer therapy: achievements and challenges that lie ahead

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Tumor control versus adverse events with targeted anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Personalizing oncology: perspectives and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Momentum grows to make 'personalized' medicine more 'precise'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Overcoming implementation challenges of personalized cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Role of folate receptor genes in reproduction and related cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Mechanisms of membrane transport of folates into cells and across epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

The folate receptor: what does it promise in tissue-targeted therapeutics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Juno is the egg Izumo receptor and is essential for mammalian fertilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

A novel splice variant of folate receptor 4 predominantly expressed in regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Influence on immunoreactive folate-binding proteins of extracellular folate concentration in cultured human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Interobserver agreement and assay reproducibility of folate receptor α expression in lung adenocarcinoma: a prognostic marker and potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Folate receptor overexpression is associated with poor outcome in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Tumor detection using folate receptor-targeted imaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Statistical and practical considerations for clinical evaluation of predictive biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Functional folate receptor alpha is elevated in the blood of ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Prognostic significance of FRA expression in epithelial cancers using AQUA(®) technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Cellular heterogeneity and molecular evolution in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Synthesis and biological evaluation of EC20: a new folate-derived, (99m)Tc-based radiopharmaceutical

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Development and preclinical evaluation of new (124)I-folate conjugates for PET imaging of folate receptor-positive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

EC145: a novel targeted agent for adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Farletuzumab in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Folate-targeted chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Engineering folate-drug conjugates to target cancer: from chemistry to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV250

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDV250

1 reference

3 September 2017

1 reference